Literature DB >> 27342567

Cardioprotection by H2S Donors: Nitric Oxide-Dependent and ‑Independent Mechanisms.

Athanasia Chatzianastasiou1, Sofia-Iris Bibli1, Ioanna Andreadou1, Panagiotis Efentakis1, Nina Kaludercic1, Mark E Wood1, Matthew Whiteman1, Fabio Di Lisa1, Andreas Daiber1, Vangelis G Manolopoulos1, Csaba Szabó1, Andreas Papapetropoulos2.   

Abstract

Hydrogen sulfide (H2S) is a signaling molecule with protective effects in the cardiovascular system. To harness the therapeutic potential of H2S, a number of donors have been developed. The present study compares the cardioprotective actions of representative H2S donors from different classes and studies their mechanisms of action in myocardial injury in vitro and in vivo. Exposure of cardiomyocytes to H2O2 led to significant cytotoxicity, which was inhibited by sodium sulfide (Na2S), thiovaline (TV), GYY4137 [morpholin-4-ium 4 methoxyphenyl(morpholino) phosphinodithioate], and AP39 [(10-oxo-10-(4-(3-thioxo-3H-1,2-dithiol5yl)phenoxy)decyl) triphenylphospho-nium bromide]. Inhibition of nitric oxide (NO) synthesis prevented the cytoprotective effects of Na2S and TV, but not GYY4137 and AP39, against H2O2-induced cardiomyocyte injury. Mice subjected to left anterior descending coronary ligation were protected from ischemia-reperfusion injury by the H2S donors tested. Inhibition of nitric oxide synthase (NOS) in vivo blocked only the beneficial effect of Na2S. Moreover, Na2S, but not AP39, administration enhanced the phosphorylation of endothelial NOS and vasodilator-associated phosphoprotein. Both Na2S and AP39 reduced infarct size in mice lacking cyclophilin-D (CypD), a modulator of the mitochondrial permeability transition pore (PTP). Nevertheless, only AP39 displayed a direct effect on mitochondria by increasing the mitochondrial Ca(2+) retention capacity, which is evidence of decreased propensity to undergo permeability transition. We conclude that although all the H2S donors we tested limited infarct size, the pathways involved were not conserved. Na2S had no direct effects on PTP opening, and its action was nitric oxide dependent. In contrast, the cardioprotection exhibited by AP39 could result from a direct inhibitory effect on PTP acting at a site different than CypD.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27342567      PMCID: PMC6047225          DOI: 10.1124/jpet.116.235119

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  64 in total

Review 1.  Ischemic postconditioning: from receptor to end-effector.

Authors:  Michael V Cohen; James M Downey
Journal:  Antioxid Redox Signal       Date:  2010-08-30       Impact factor: 8.401

2.  Exogenous hydrogen sulfide (H2S) protects against regional myocardial ischemia-reperfusion injury--Evidence for a role of K ATP channels.

Authors:  David Johansen; Kirsti Ytrehus; Gary F Baxter
Journal:  Basic Res Cardiol       Date:  2005-11-21       Impact factor: 17.165

Review 3.  Cyclophilin D in mitochondrial pathophysiology.

Authors:  Valentina Giorgio; Maria Eugenia Soriano; Emy Basso; Elena Bisetto; Giovanna Lippe; Michael A Forte; Paolo Bernardi
Journal:  Biochim Biophys Acta       Date:  2009-12-21

4.  AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro.

Authors:  Bartosz Szczesny; Katalin Módis; Kazunori Yanagi; Ciro Coletta; Sophie Le Trionnaire; Alexis Perry; Mark E Wood; Matthew Whiteman; Csaba Szabo
Journal:  Nitric Oxide       Date:  2014-04-19       Impact factor: 4.427

Review 5.  Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease.

Authors:  David J Polhemus; David J Lefer
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

Review 6.  Enzymology of H2S biogenesis, decay and signaling.

Authors:  Omer Kabil; Ruma Banerjee
Journal:  Antioxid Redox Signal       Date:  2013-06-07       Impact factor: 8.401

7.  Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression.

Authors:  Elisabetta Panza; Paola De Cicco; Chiara Armogida; Giosuè Scognamiglio; Vincenzo Gigantino; Gerardo Botti; Domenico Germano; Maria Napolitano; Andreas Papapetropoulos; Mariarosaria Bucci; Giuseppe Cirino; Angela Ianaro
Journal:  Pigment Cell Melanoma Res       Date:  2014-10-06       Impact factor: 4.693

Review 8.  Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent.

Authors:  Derek J Hausenloy; E A Boston-Griffiths; D M Yellon
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

9.  Design, Synthesis, and Cardioprotective Effects of N-Mercapto-Based Hydrogen Sulfide Donors.

Authors:  Yu Zhao; Chuntao Yang; Chelsea Organ; Zhen Li; Shashi Bhushan; Hiro Otsuka; Armando Pacheco; Jianming Kang; Hector C Aguilar; David J Lefer; Ming Xian
Journal:  J Med Chem       Date:  2015-09-04       Impact factor: 7.446

Review 10.  Hydrogen sulfide prodrugs-a review.

Authors:  Yueqin Zheng; Xingyue Ji; Kaili Ji; Binghe Wang
Journal:  Acta Pharm Sin B       Date:  2015-08-21       Impact factor: 11.413

View more
  21 in total

Review 1.  Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.

Authors:  Jacek Zielonka; Joy Joseph; Adam Sikora; Micael Hardy; Olivier Ouari; Jeannette Vasquez-Vivar; Gang Cheng; Marcos Lopez; Balaraman Kalyanaraman
Journal:  Chem Rev       Date:  2017-06-27       Impact factor: 60.622

2.  Hydrogen Sulfide Donor GYY4137 Acts Through Endothelial Nitric Oxide to Protect Intestine in Murine Models of Necrotizing Enterocolitis and Intestinal Ischemia.

Authors:  Natalie A Drucker; Amanda R Jensen; Jan P Te Winkel; Troy A Markel
Journal:  J Surg Res       Date:  2018-10-23       Impact factor: 2.192

3.  AP39, a mitochondria-targeting hydrogen sulfide (H2 S) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling.

Authors:  Qutuba G Karwi; Julia Bornbaum; Kerstin Boengler; Roberta Torregrossa; Matthew Whiteman; Mark E Wood; Rainer Schulz; Gary F Baxter
Journal:  Br J Pharmacol       Date:  2017-01-24       Impact factor: 8.739

4.  Nitrosopersulfide (SSNO-) decomposes in the presence of sulfide, cyanide or glutathione to give HSNO/SNO-: consequences for the assumed role in cell signalling.

Authors:  Rudolf Wedmann; Ivana Ivanovic-Burmazovic; Milos R Filipovic
Journal:  Interface Focus       Date:  2017-04-06       Impact factor: 3.906

Review 5.  Beyond a Gasotransmitter: Hydrogen Sulfide and Polysulfide in Cardiovascular Health and Immune Response.

Authors:  Shuai Yuan; Xinggui Shen; Christopher G Kevil
Journal:  Antioxid Redox Signal       Date:  2017-06-01       Impact factor: 8.401

Review 6.  Regulation of Aqueous Humor Dynamics by Hydrogen Sulfide: Potential Role in Glaucoma Pharmacotherapy.

Authors:  Sunny E Ohia; Jenaye Robinson; Leah Mitchell; Kalu K Ngele; Segewkal Heruye; Catherine A Opere; Ya Fatou Njie-Mbye
Journal:  J Ocul Pharmacol Ther       Date:  2017-12-07       Impact factor: 2.671

Review 7.  International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors.

Authors:  Csaba Szabo; Andreas Papapetropoulos
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

8.  Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.

Authors:  Ioanna Andreadou; Panagiotis Efentakis; Evangelos Balafas; Gabriele Togliatto; Constantinos H Davos; Aimilia Varela; Constantinos A Dimitriou; Panagiota-Efstathia Nikolaou; Eirini Maratou; Vaia Lambadiari; Ignatios Ikonomidis; Nikolaos Kostomitsopoulos; Maria F Brizzi; George Dimitriadis; Efstathios K Iliodromitis
Journal:  Front Physiol       Date:  2017-12-19       Impact factor: 4.566

9.  Nitroglycerine limits infarct size through S-nitrosation of cyclophilin D: a novel mechanism for an old drug.

Authors:  Sofia-Iris Bibli; Andreas Papapetropoulos; Efstathios K Iliodromitis; Andreas Daiber; Voahanginirina Randriamboavonjy; Sebastian Steven; Peter Brouckaert; Athanasia Chatzianastasiou; Kyriakos E Kypreos; Derek J Hausenloy; Ingrid Fleming; Ioanna Andreadou
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

10.  The novel mitochondria-targeted hydrogen sulfide (H2S) donors AP123 and AP39 protect against hyperglycemic injury in microvascular endothelial cells in vitro.

Authors:  Domokos Gerő; Roberta Torregrossa; Alexis Perry; Alicia Waters; Sophie Le-Trionnaire; Jacqueline L Whatmore; Mark Wood; Matthew Whiteman
Journal:  Pharmacol Res       Date:  2016-08-23       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.